Overview
Description
BioNTech SE is a biotechnology company, represented in the financial market through American Depositary Receipts (ADRs). This setup allows American investors to own shares in BioNTech, a German-based enterprise, without dealing with foreign equities directly. BioNTech SE is renowned for its research and development in personalized immunotherapies and pioneering work in developing mRNA-based drugs and vaccines. This company came into global prominence through the rapid development and deployment of its COVID-19 vaccine, in collaboration with Pfizer.
BioNTech's core operations focus on advancing a variety of therapeutic areas, including oncology, infectious diseases, and regenerative medicine. Their contributions have significantly impacted the healthcare and pharmaceutical sectors by promoting innovation in vaccine technology and personalized medicine solutions. In the financial markets, BioNTech SE's ADRs represent its dynamic role as a trailblazer in biotech innovation, offering investors exposure to the promising sectors of biotechnology and healthcare. The company's expertise in utilizing breakthroughs in mRNA technology underscores its market significance and the potential for substantial contributions to global medicine and public health.
About
CEO
Dr. Ugur Sahin M.D.
Employees
6772
Address
An der Goldgrube 12
Mainz, 55131
Mainz, 55131
Phone
49 6131 9084
Website
Instrument type
Depositary receipt
Sector
Healthcare
Industry
Biotechnology
Country
United States
MIC code
XNGS